On Friday, June 2, 2023, at ASCO, CancerX – a public-private partnership co-hosted by Moffitt Cancer Center and the Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH) – announced its founding members:
1104Health
AARDEX Group
Amazon Web Services (AWS)
American Cancer Society
ASCO CancerLinQ
AstraZeneca
Athelo Health
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Atrium Health Levine Cancer Institute
Autonomize, Inc.
Avellino
Banner MD Anderson Cancer Center
Biofourmis
Biohacking Village
Blue Note Therapeutics
Blue Spark Technologies, Inc.
Bulldog Medical, Inc.
C the Signs
Canadian Cancer Society
Cancer Support Community
Carium
City of Hope
Clario
Current Health, A Best Buy Health Company
Dana-Farber Cancer Institute
Datavant
Elevance Health
Emerson Collective Health
Empatica
Family Reach
Flatiron Health
Foley & Lardner LLP
Folia Health
Genentech, a member of the Roche group
Genomate Health
Graphite Health
Gray Oncology Solutions
Haystack Health
Health Chain
Health Wallet
Hike Health
HunterSeven Foundation
Hurone AI
Intel
Jasper Health
Kaiser Permanente
Leukemia & Lymphoma Society
Light Collective
Lightship Inc
Lunit
Luscii
MassChallenge
Massive Bio
MD Anderson
Medable
MEND Nutrition
Memorial Sloan Kettering Cancer Center (MSK)
Navio Theragnostics, Inc.
National Cancer Institute (NCI)
NorthShore—Edward-Elmhurst Health
OncoPower
Oracle
Orchid Healthcare Solutions
Outcomes4Me
Pluto Health
Point32Health Inc
Power
Qritive Pte Ltd
RestAssured MD
Rubix LS
Savvy Cooperative
Science 37
Sidekick Health
Siemens Healthineers
SimBioSys, Inc.
Slope
Socially Determined
Sophia Genetics
Soteria
State of Colorado
Takeda
Takeda Digital Ventures
Tempus
The Janssen Pharmaceutical Companies of Johnson & Johnson
Thyme Care
Touch BBCA
Tulsa Innovation Labs (TIL)
UC Davis Health
UChicago Medicine
Veris Health
VivoSense
Volpara Health
This group will drive the success of CancerX, collaborating to set priorities and practices that will help us harness the full power of innovation to achieve the goals of the Cancer Moonshot.
Thursday, May 25, ASCO also published two online abstracts from CancerX:
“CancerX: A national public-private partnership to boost innovation in the fight against cancer,” which outlines CancerX’s multi-pronged approach focused on 1) commoditizing best practices and aligning incentives, 2) coordinating access to research, mentorship, resources, and other collaborative opportunities, and 3) demonstrating success in practice to drive broad adoption – all the achieve the goal of reducing the incidence and burden of cancer for all people.
“Advancing digital innovation to improve equity and reduce financial toxicity in cancer treatment,” which details CancerX’s inaugural project to define the value of digital innovation in cancer treatment, address methodological and implementation gaps, and develop best practices for equitable adoption of digital health technologies at scale in precision oncology.
Background on CancerX:
CancerX was announced by U.S. President Joe Biden and Dr. Jill Biden in February 2023 as part of The White House’s reignited national Cancer Moonshot initiative.
The public-private partnership unites the diverse stakeholders and innovators necessary to unleash the power of digital innovation to design and create a future that’s free of the burden of cancer.
At the end of March 2023, CancerX announced its co-hosts: Moffitt Cancer Center and the Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH). It also announced its inaugural project, “Advancing Digital Innovation to Improve Equity and Reduce Financial Toxicity in Cancer Care and Research,” which has begun work to assess, quantify, and enhance the impact of digital solutions on cancer care cost, access, and outcomes dimensions.
Sign up to receive information on this news and other CancerX work.